Glenmark Pharmaceuticals is going to introduce a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day. The 200 mg dosage of FabiFlu required patients to take 18 tablets on Day 1, followed by 8 tablets each day thereafter for a maximum of 14 days. With the new 400 mg version, patients will now have a more relaxed dosage regimen, with 9 tablets required on Day 1, and thereafter 2 tablets twice a day from Day 2 till end of the course.
Dr Monika Tandon, Vice President & Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals Ltd., said, “Being the first company to launch Favipiravir in India, we continue to innovate and seek new treatment options for Covid-19 patients. Introducing this higher strength of FabiFlu is in line with these efforts to ensure a smoother experience for patients, by reducing their daily pill burden. The 200 mg dosage of FabiFlu was developed in line with global formulations of the drug Favipiravir and the 400 mg version is a result of Glenmark’s own R&D efforts to improve the treatment experience for patients in India.”
